Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price dropped by research analysts at Needham & Company LLC from $42.00 to $32.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 63.60% from the company’s previous close.

VRDN has been the subject of a number of other reports. UBS Group began coverage on Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. Truist Financial cut their target price on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Wedbush reissued an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, March 11th. Finally, William Blair assumed coverage on Viridian Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics Stock Up 5.6%

Shares of NASDAQ VRDN opened at $19.56 on Monday. The company has a 50 day simple moving average of $29.16 and a 200 day simple moving average of $27.89. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $34.29. The firm has a market cap of $2.00 billion, a PE ratio of -5.95 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, research analysts forecast that Viridian Therapeutics will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VRDN. Simplify Asset Management Inc. acquired a new position in shares of Viridian Therapeutics in the 3rd quarter valued at about $1,079,000. Hudson Bay Capital Management LP grew its stake in Viridian Therapeutics by 46.6% during the third quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after purchasing an additional 55,689 shares during the period. Fisher Asset Management LLC grew its stake in Viridian Therapeutics by 135.6% during the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock worth $25,922,000 after purchasing an additional 691,267 shares during the period. Propel Bio Management LLC bought a new stake in Viridian Therapeutics in the third quarter worth approximately $1,942,000. Finally, Y Intercept Hong Kong Ltd increased its holdings in Viridian Therapeutics by 430.3% in the third quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock worth $1,394,000 after purchasing an additional 52,414 shares in the last quarter.

Key Stories Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.